Atypical clinical manifestations and genotype-phenotype correlations of neurofibromatosis type 1

Purpose of the study: Analysis of available data on geno-phenotypic correlations and atypical forms of neurofibromatosis type 1. Material and methods. We searched for relevant sources in the Scopus, Web of Science, PubMed systems, including publications from May 1993 to October 2021. Of the 318 studies  we identified, 59 were used to write a systematic review. Results. We found studies describing atypical forms of neurofibromatosis type 1 with an erased course without manifestation of a tumor syndrome, which are caused by specific mutations in the NF1 gene (causing substitutions of amino acids in neurofibromin: p.Arg1038, p.Met1149, p.Arg1809, or deletion of amino acids: p.Met990del, p.Met992del). NF1 patients with microdeletions are characterized by more severe disease symptoms (more often facial dysmorphism, skeletal and cardiovascular abnormalities, learning difficulties, and symptomatic spinal neurofibromas). mutations of splicing sites and extended deletions of the NF1 gene are associated with early manifestation of tumors, mutations at the 5’-end of the gene, causing a shortening of the protein product, are associated with optic nerve gliomas. the mutation c.3721C>T (p.R1241*) correlated with structural brain damage, and c.6855C>A (p.Y2285*)  with  endocrine  disorders. the  manifestations  of  NF1,  similar  to  lipomatosis  and Jaffe-Campanacci syndrome, not associated with a specific type of mutation are described. Conclusion.  In spite of pronounced clinical variability of the disease, even among members of the same family, several studies have described genotype-phenotype correlations. Therefore, the role of modifier genes and epigenetic factors in the pathogenesis of NF1 is assumed, since the neurofibromin protein has a complex structure with several functional domains. It has been shown that the severity of the tumor syndrome is influenced by the methylation characteristics of NF1 gene and adjacent areas. in addition, NF1 gene is associated with a variety of microRNAs. therefore, targeted therapy aimed at specific non-coding RNAs to restore normal expression of NF1 gene can become a promising treatment for NF1.

1. Koczkowska M., Callens T., Gomes A., Sharp A., Chen Y., Hicks A.D., Aylsworth A.S., Azizi A.A., Basel D.G., Bellus G., Bird L.M., Blazo M.A., Burke L.W., Cannon A., Collins F., DeFilippo C., Denayer E., Digilio M.C., Dills S.K., Dosa L., Greenwood R.S., Griffis C., Gupta P., Hachen R.K., Hernández-Chico C., Janssens S., Jones K.J., Jordan J.T., Kannu P., Korf B.R., Lewis A.M., Listernick R.H., Lonardo F., Mahoney M.J., Ojeda M.M., McDonald M.T., McDougall C., Mendelsohn N., Miller D.T., Mori M., Oostenbrink R., Perreault S., Pierpont M.E., Piscopo C., Pond D.A., Randolph L.M., Rauen K.A., Rednam S., Rutledge S.L., Saletti V., Schaefer G.B., Schorry E.K., Scott D.A., Shugar A., Siqveland E., Starr L.J., Syed A., Trapane P.L., Ullrich N.J., Wakefield E.G., Walsh L.E., Wangler M.F., Zackai E., Claes K.B.M., Wimmer K., van Minkelen R., De Luca A., Martin Y., Legius E., Messiaen L.M. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019; 21(4): 867–76. doi: 10.1038/s41436-018-0269-0.

2. Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N., Giovannini S., Evans D.G., Howard E., Kerr B., Griffiths S., Consoli C., Side L., Adams D., Pierpont M., Hachen R., Barnicoat A., Li H., Wallace P., Van Biervliet J.P., Stevenson D., Viskochil D., Baralle D., Haan E., Riccardi V., Turnpenny P., Lazaro C., Messiaen L. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007; 80(1): 140–51. doi: 10.1086/510781.

3. Yu Y., Choi K., Wu J., Andreassen P.R., Dexheimer P.J., Keddache M., Brems H., Spinner R.J., Cancelas J.A., Martin L.J., Wallace M.R., Legius E., Vogel K.S., Ratner N. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathol. 2020; 139(1): 157–74. doi: 10.1007/s00401-019-02086-w.

4. Tabata M.M., Li S., Knight P., Bakker A., Sarin K.Y. Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry. JCI Insight. 2020; 5(16). doi: 10.1172/jci.insight.136262.

5. Beert E., Brems H., Daniëls B., De Wever I., Van Calenbergh F., Schoenaers J., Debiec-Rychter M., Gevaert O., De Raedt T., Van Den Bruel A., de Ravel T., Cichowski K., Kluwe L., Mautner V., Sciot R., Legius E. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011; 50(12): 1021–32. doi: 10.1002/gcc.20921.

6. Barrea C., Vaessen S., Bulk S., Harvengt J., Misson J.P. Phenotype-Genotype Correlation in Children with Neurofibromatosis Type 1. Neuropediatrics. 2018; 49(3): 180–4. doi: 10.1055/s-0037-1620239.

7. Rojnueangnit K., Xie J., Gomes A., Sharp A., Callens T., Chen Y., Liu Y., Cochran M., Abbott M.A., Atkin J., Babovic-Vuksanovic D., Barnett C.P., Crenshaw M., Bartholomew D.W., Basel L., Bellus G., BenShachar S., Bialer M.G., Bick D., Blumberg B., Cortes F., David K.L., Destree A., Duat-Rodriguez A., Earl D., Escobar L., Eswara M., Ezquieta B., Frayling I.M., Frydman M., Gardner K., Gripp K.W., Hernández-Chico C., Heyrman K., Ibrahim J., Janssens S., Keena B.A., Llano-Rivas I., Leppig K., McDonald M., Misra V.K., Mulbury J., Narayanan V., Orenstein N., Galvin-Parton P., Pedro H., Pivnick E.K., Powell C.M., Randolph L., Raskin S., Rosell J., Rubin K., Seashore M., Schaaf C.P., Scheuerle A., Schultz M., Schorry E., Schnur R., Siqveland E., Tkachuk A., Tonsgard J., Upadhyaya M., Verma I.C., Wallace S., Williams C., Zackai E., Zonana J., Lazaro C., Claes K., Korf B., Martin Y., Legius E., Messiaen L. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat. 2015; 36(11): 1052–63. doi: 10.1002/humu.22832.

8. Rodenhiser D.I., Ainsworth P.J., Coulter-Mackie M.B., Singh S.M., Jung J.H. A genetic study of neurofibromatosis type 1 (NF1) in south-western Ontario. II. A PCR based approach to molecular and prenatal diagnosis using linkage. J Med Genet. 1993; 30(5): 363–8. doi: 10.1136/jmg.30.5.363.

9. Ratner N., Miller S.J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015; 15(5): 290–301. doi: 10.1038/nrc3911.

10. Quintáns B., Pardo J., Campos B., Barros F., Volpini V., Carracedo A., Sobrido M.J. Neurofibromatosis without Neurofibromas: Confirmation of a Genotype-Phenotype Correlation and Implications for Genetic Testing. Case Rep Neurol. 2011; 3(1): 86–90. doi: 10.1159/000327557.

11. Büki G., Zsigmond A., Czakó M., Szalai R., Antal G., Farkas V., Fekete G., Nagy D., Széll M., Tihanyi M., Melegh B., Hadzsiev K., Bene J. Genotype-Phenotype Associations in Patients With Type-1, Type-2, and Atypical NF1 Microdeletions. Front Genet. 2021; 12. doi: 10.3389/fgene.2021.673025.

12. Melean G., Hernández A.M., Valero M.C., Hernández-Imaz E., Martín Y., Hernández-Chico C. Monozygotic twins with Neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasis. BMC Cancer. 2010; 10: 407. doi: 10.1186/1471-2407-10-407.

13. Kaplan L., Foster R., Shen Y., Parry D.M., McMaster M.L., O’Leary M.C., Gusella J.F. Monozygotic twins discordant for neurofibromatosis 1. Am J Med Genet A. 2010; 152A(3): 601–6. doi: 10.1002/ajmg.a.33271.

14. Sumner K., Crockett D.K., Muram T., Mallempati K., Best H., Mao R. The SPRED1 Variants Repository for Legius Syndrome. G3 (Bethesda). 2011; 1(6): 451–6. doi: 10.1534/g3.111.000687.

15. Miraglia E., Fino P., Lopez T., Iacovino C., Calvieri S., Giustini S. Multiple lipomas in a patient with Neurofibromatosis Type 1. G Ital Dermatol Venereol. 2019; 154(6): 734–5. doi: 10.23736/S0392-0488.18.05869-8.

16. Miraglia E., Calvieri S., Giustini S. Lipomas in neurofibromatosis type 1: a single-institution experience. G Ital Dermatol Venereol. 2020; 155(3): 375–6. doi: 10.23736/S0392-0488.18.06044-3.

17. Ramirez E., Morris S.M., Turner T.N., Gutmann D.H. Familial Lipomas Without Classic Neurofibromatosis-1 Caused by a Missense Germline NF1 Mutation. Neurol Genet. 2021; 7(3). doi: 10.1212/NXG.0000000000000582.

18. Koczkowska M., Callens T., Chen Y., Gomes A., Hicks A.D., Sharp A., Johns E., Uhas K.A., Armstrong L., Bosanko K.A., Babovic-Vuksanovic D., Baker L., Basel D.G., Bengala M., Bennett J.T., Chambers C., Clarkson L.K., Clementi M., Cortés F.M., Cunningham M., D'Agostino M.D., Delatycki M.B., Digilio M.C., Dosa L., Esposito S., Fox S., Freckmann M.L., Fauth C., Giugliano T., Giustini S., Goetsch A., Goldberg Y., Greenwood R.S., Griffis C., Gripp K.W., Gupta P., Haan E., Hachen R.K., Haygarth T.L., Hernández-Chico C., Hodge K., Hopkin R.J., Hudgins L., Janssens S., Keller K., Kelly-Mancuso G., Kochhar A., Korf B.R., Lewis A.M., Liebelt J., Lichty A., Listernick R.H., Lyons M.J., Maystadt I., Martinez Ojeda M., Mc-Dougall C., McGregor L.K., Melis D., Mendelsohn N., Nowaczyk M.J.M., Ortenberg J., Panzer K., Pappas J.G., Pierpont M.E., Piluso G., Pinna V., Pivnick E.K., Pond D.A., Powell C.M., Rogers C., Ruhrman Shahar N., Rutledge S.L., Saletti V., Sandaradura S.A., Santoro C., Schatz U.A., Schreiber A., Scott D.A., Sellars E.A., Sheffer R., Siqveland E., Slopis J.M., Smith R., Spalice A., Stockton D.W., Streff H., Theos A., Tomlinson G.E., Tran G., Trapane P.L., Trevisson E., Ullrich N.J., Van den Ende J., Schrier Vergano S.A., Wallace S.E., Wangler M.F., Weaver D.D., Yohay K.H., Zackai E., Zonana J., Zurcher V., Claes K.B.M., Eoli M., Martin Y., Wimmer K., De Luca A., Legius E., Messiaen L.M. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020; 41(1): 299–315. doi: 10.1002/humu.23929.

19. Lee C.H., Spence R.A., Upadhyaya M., Morrison P.J. Familial multiple lipomatosis with clear autosomal dominant inheritance and onset in early adolescence. BMJ Case Rep. 2011. doi: 10.1136/bcr.10.2010.3395.

20. Lee S., Bak H., Ahn S.K. Liponeurofibroma: Clinicopathological features and histogenesis. J Dermatol. 2018; 45(4): 416–24. doi: 10.1111/1346-8138.14238.

21. Miettinen M.M., Antonescu C.R., Fletcher C.D.M., Kim A., Lazar A.J., Quezado M.M., Reilly K.M., Stemmer-Rachamimov A., Stewart D.R., Viskochil D., Widemann B., Perry A. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017; 67: 1–10. doi: 10.1016/j.humpath.2017.05.010.

22. Stewart D.R., Brems H., Gomes A.G., Ruppert S.L., Callens T., Williams J., Claes K., Bober M.B., Hachen R., Kaban L.B., Li H., Lin A., McDonald M., Melancon S., Ortenberg J., Radtke H.B., Samson I., Saul R.A., Shen J., Siqveland E., Toler T.L., van Maarle M., Wallace M., Williams M., Legius E., Messiaen L. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. Genet Med. 2014; 16(6): 448–59. doi: 10.1038/gim.2013.163.

23. Rahal N., Sadi A., Cohen-Barak E., Ziv M., Krausz J., Dodiuk-Gad R.P. LEPOARD syndrome: A report of a case with a novel PTPN11 mutation. JAAD Case Rep. 2021; 11: 57–9. doi: 10.1016/j.jdcr.2021.03.022.

24. Trevisson E., Morbidoni V., Forzan M., Daolio C., Fumini V., Parrozzani R., Cassina M., Midena E., Salviati L., Clementi M. The Arg1038Gly missense variant in the NF1 gene causes a mild phenotype without neurofibromas. Mol Genet Genomic Med. 2019; 7(5). doi: 10.1002/mgg3.616.

25. Pasmant E., Sabbagh A., Spurlock G., Laurendeau I., Grillo E., Hamel M.J., Martin L., Barbarot S., Leheup B., Rodriguez D., Lacombe D., Dollfus H., Pasquier L., Isidor B., Ferkal S., Soulier J., Sanson M., Dieux-Coeslier A., Bièche I., Parfait B., Vidaud M., Wolkenstein P., Upadhyaya M., Vidaud D.; members of the NF France Network. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010; 31(6): 1506–18. doi: 10.1002/humu.21271.

26. Pacot L., Vidaud D., Sabbagh A., Laurendeau I., Briand-Suleau A., Coustier A., Maillard T., Barbance C., Morice-Picard F., Sigaudy S., Glazunova O.O., Damaj L., Layet V., Quelin C., Gilbert-Dussardier B., Audic F., Dollfus H., Guerrot A.M., Lespinasse J., Julia S., Vantyghem M.C., Drouard M., Lackmy M., Leheup B., Alembik Y., Lemaire A., Nitschké P., Petit F., Dieux Coeslier A., Mutez E., Taieb A., Fradin M., Capri Y., Nasser H., Ruaud L., Dauriat B., Bourthoumieu S., Geneviève D., Audebert-Bellanger S., Nizon M., Stoeva R., Hickman G., Nicolas G., Mazereeuw-Hautier J., Jannic A., Ferkal S., Parfait B., Vidaud M., Members Of The Nf France Network, Wolkenstein P., Pasmant E. Severe Phenotype in Patients with Large Deletions of NF1. Cancers (Basel). 2021; 13(12): 2963. doi: 10.3390/cancers13122963.

27. Kang E., Kim Y.M., Seo G.H., Oh A., Yoon H.M., Ra Y.S., Kim E.K., Kim H., Heo S.H., Kim G.H., Osborn M.J., Tolar J., Yoo H.W., Lee B.H. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. J Hum Genet. 2020; 65(2): 79–89. doi: 10.1038/s10038-019-0695-0.

28. Alkindy A., Chuzhanova N., Kini U., Cooper D.N., Upadhyaya M. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? Hum Genomics. 2012; 6(1): 12. doi: 10.1186/1479-7364-6-12.

29. Anastasaki C., Morris S.M., Gao F., Gutmann D.H. Children with 5’-end NF1 gene mutations are more likely to have glioma. Neurol Genet. 2017; 3(5): 192. doi: 10.1212/NXG.0000000000000192.

30. Morris S.M., Gutmann D.H. A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. Neurology. 2018; 90(8): 377–9. doi: 10.1212/WNL.0000000000005000.

31. Frayling I.M., Mautner V.F., van Minkelen R., Kallionpaa R.A., Aktaş S., Baralle D., Ben-Shachar S., Callaway A., Cox H., Eccles D.M., Ferkal S., LaDuca H., Lázaro C., Rogers M.T., Stuenkel A.J., Summerour P., Varan A., Yap Y.S., Zehou O., Peltonen J., Evans D.G., Wolkenstein P., Upadhyaya M. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet. 2019; 56(4): 209–19. doi: 10.1136/jmedgenet-2018-105599.

32. Upadhyaya M., Spurlock G., Kluwe L., Chuzhanova N., Bennett E., Thomas N., Guha A., Mautner V. The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas. Neurogenetics. 2009; 10(3): 251–63. doi: 10.1007/s10048-009-0178-0.

33. Pinna V., Lanari V., Daniele P., Consoli F., Agolini E., Margiotti K., Bottillo I., Torrente I., Bruselles A., Fusilli C., Ficcadenti A., Bargiacchi S., Trevisson E., Forzan M., Giustini S., Leoni C., Zampino G., Digilio M.C., Dallapiccola B., Clementi M., Tartaglia M., De Luca A. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet. 2015; 23(8): 1068–71. doi: 10.1038/ejhg.2014.243.

34. Scala M., Schiavetti I., Madia F., Chelleri C., Piccolo G., Accogli A., Riva A., Salpietro V., Bocciardi R., Morcaldi G., Di Duca M., Caroli F., Verrico A., Milanaccio C., Viglizzo G., Traverso M., Baldassari S., Scudieri P., Iacomino M., Piatelli G., Minetti C., Striano P., Garrè M.L., De Marco P., Diana M.C., Capra V., Pavanello M., Zara F. Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study. Cancers (Basel). 2021; 13(8): 1879. doi: 10.3390/cancers13081879.

35. Sharafi P., Ayter S. Possible modifier genes in the variation of neurofibromatosis type 1 clinical phenotypes. J Neurogenet. 2018; 32(2): 65–77. doi: 10.1080/01677063.2018.1456538.

36. Sung H., Hyland P.L., Pemov A., Sabourin J.A., Baldwin A.M., Bass S., Teshome K., Luo W.; Frederick National Laboratory for Cancer Research, Widemann B.C., Stewart D.R., Wilson A.F. Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1. Mol Genet Genomic Med. 2020; 8(10): 1400. doi: 10.1002/mgg3.1400.

37. Woycinck Kowalski T., Brussa Reis L., Finger Andreis T., Ashton-Prolla P., Rosset C. Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1. Cancers (Basel). 2020; 12(9): 2416. doi: 10.3390/cancers12092416.

38. Warrington N.M., Sun T., Luo J., McKinstry R.C., Parkin P.C., Ganzhorn S., Spoljaric D., Albers A.C., Merkelson A., Stewart D.R., Stevenson D.A., Viskochil D., Druley T.E., Forys J.T., Reilly K.M., Fisher M.J., Tabori U., Allen J.C., Schiffman J.D., Gutmann D.H., Rubin J.B. The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. Cancer Res. 2015; 75(1): 16–21. doi: 10.1158/0008-5472.CAN-14-1891.

39. Karaosmanoglu B., Kocaefe Ç.Y., Söylemezoğlu F., Anlar B., Varan A., Vargel İ., Ayter S. Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas. Childs Nerv Syst. 2018; 34(5): 877–82. doi: 10.1007/s00381-018-3745-6.

40. Yang F., Xu S., Liu R., Shi T., Li X., Li X., Chen G., Liu H., Zhou Q., Chen J. The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing. Onco Targets Ther. 2018; 11: 919–32. doi: 10.2147/OTT.S156998.

41. Sant D.W., Margraf R.L., Stevenson D.A., Grossmann A.H., Viskochil D.H., Hanson H., Everitt M.D., Rios J.J., Elefteriou F., Hennessey T., Mao R. Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1. J Med Genet. 2015; 52(4): 256–61. doi: 10.1136/jmedgenet-2014-102815.

42. Ma Y., Gross A.M., Dombi E., Pemov A., Choi K., Chaney K., Rhodes S.D., Angus S.P., Sciaky N., Clapp D.W., Ratner N., Widemann B.C., Rios J.J., Elefteriou F. A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genet Med 2020. 22: 1786–93. doi: 10.1038/s41436-020-0885-3.

43. Fishbein L., Eady B., Sanek N., Muir D., Wallace M.R. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer Genet Cytogenet. 2005; 157(2): 181–6. doi: 10.1016/j.cancergencyto.2004.08.016.

44. Horan M.P., Cooper D.N., Upadhyaya M. Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. Hum Genet. 2000; 107(1): 33–9. doi: 10.1007/s004390000322.

45. Zou M.X., Butcher D.T., Sadikovic B., Groves T.C., Yee S.P., Rodenhiser D.I. Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region. Oncogene. 2004; 23(2): 330–9. doi: 10.1038/sj.onc.1207053.

46. Hajra A., Martin-Gallardo A., Tarlé S.A., Freedman M., Wilson-Gunn S., Bernards A., Collins F.S. DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse. Genomics. 1994; 21(3): 649–52. doi: 10.1006/geno.1994.1328.

47. Haines T.R., Rodenhiser D.I., Ainsworth P.J. Allele-specific non-CpG methylation of the Nf1 gene during early mouse development. Dev Biol. 2001; 240(2): 585–98. doi: 10.1006/dbio.2001.0504.

48. Harder A., Titze S., Herbst L., Harder T., Guse K., Tinschert S., Kaufmann D., Rosenbaum T., Mautner V.F., Windt E., Wahlländer-Danek U., Wimmer K., Mundlos S., Peters H. Monozygotic twins with neurofibromatosis type 1 (NF1) display differences in methylation of NF1 gene promoter elements, 5’ untranslated region, exon and intron 1. Twin Res Hum Genet. 2010; 13(6): 582–94. doi: 10.1375/twin.13.6.582. PMID: 21142935.

49. Lu H., Liu P., Pang Q. MiR-27a-3p/miR-27b-3p Promotes Neurofibromatosis Type 1 via Targeting of NF1. J Mol Neurosci. 2021; 71(11): 2353–63. doi: 10.1007/s12031-020-01779-2.

50. Paschou M., Doxakis E. Neurofibromin 1 is a miRNA target in neurons. PLoS One. 2012; 7(10). doi: 10.1371/journal.pone.0046773.

51. Stark M.S., Bonazzi V.F., Boyle G.M., Palmer J.M., Symmons J., Lanagan C.M., Schmidt C.W., Herington A.C., Ballotti R., Pollock P.M., Hayward N.K. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget. 2015; 6(19): 17753–63. doi: 10.18632/oncotarget.3924.

52. Wang S., Ma G., Zhu H., Lv C., Chu H., Tong N., Wu D., Qiang F., Gong W., Zhao Q., Tao G., Zhou J., Zhang Z., Wang M. miR-107 regulates tumor progression by targeting NF1 in gastric cancer. Sci Rep. 2016; 6: 36531. doi: 10.1038/srep36531.

53. Guo L., Li B., Yang J., Shen J., Ji J., Miao M. Fibroblastderived exosomal microRNA369 potentiates migration and invasion of lung squamous cell carcinoma cells via NF1mediated MAPK signaling pathway. Int J Mol Med. 2020; 46(2): 595–608. doi: 10.3892/ijmm.2020.4614.

54. Na Y., Hall A., Choi K., Hu L., Rose J., Coover R.A., Miller A., Hennigan R.F., Dombi E., Kim M.O., Subramanian S., Ratner N., Wu J. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene. 2021; 40(5): 951–63. doi: 10.1038/s41388-020-01581-9.

55. Chai G., Liu N., Ma J., Li H., Oblinger J.L., Prahalad A.K., Gong M., Chang L.S., Wallace M., Muir D., Guha A., Phipps R.J., Hock J.M., Yu X. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci. 2010; 101(9): 1997–2004. doi: 10.1111/j.1349-7006.2010.01616.x.

56. Wang M., Wang Z., Zhu X., Guan S., Liu Z. NFKB1-miR-612-FAIM2 pathway regulates tumorigenesis in neurofibromatosis type 1. In Vitro Cell Dev Biol Anim. 2019; 55(7): 491–500. doi: 10.1007/s11626-019-00370-3.

57. Su J., Ruan S., Dai S., Mi J., Chen W., Jiang S. NF1 regulates apoptosis in ovarian cancer cells by targeting MCL1 via miR-142-5p. Pharmacogenomics. 2019; 20(3): 155–65. doi: 10.2217/pgs-2018-0161.

58. Pasmant E., Sabbagh A., Masliah-Planchon J., Ortonne N., Laurendeau I., Melin L., Ferkal S., Hernandez L., Leroy K., Valeyrie-Allanore L., Parfait B., Vidaud D., Bièche I., Lantieri L., Wolkenstein P., Vidaud M.; NF France Network. Role of noncoding RNAANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1. J Natl Cancer Inst. 2011; 103(22): 1713–22. doi: 10.1093/jnci/djr416.

59. Riccardi C., Perrone L., Napolitano F., Sampaolo S., Melone M.A.B. Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design. Cancers (Basel). 2020; 12(10): 2965. doi: 10.3390/cancers12102965.